WST (West Pharmaceutical Services) Tariff Resilience Score: 6/10 (As of Jun. 24, 2026)


WST West Pharmaceutical Services Inc WST
95 GF Score
Price $341.96
GF Value $361.52
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is West Pharmaceutical Services Tariff Resilience Score?

West Pharmaceutical Services WST +1.66% 95 Tariff Resilience Score is 6 as of Jun. 24, 2026. GuruFocus rates WST with a GF Score™ of 95/100 and a GF Value™ of $361.52 (Fairly Valued). The stock has 9 warning signs investors should review. Among 838 Medical Devices & Instruments companies, West Pharmaceutical Services ranks better than 90.93% on this metric.

West Pharmaceutical Services has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

West Pharmaceutical Services has West Pharmaceutical Services has a global manufacturing footprint, which exposes it to tariffs. However, its strong market position and ability to pass costs to customers provide some mitigation. Previous tariff impacts have been managed effectively.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes West Pharmaceutical Services might have Average Resilient.

West Pharmaceutical Services  (NYSE:WST) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

West Pharmaceutical Services Tariff Resilience Score Related Terms

WST vs RMD, MDLN, SOLV: Tariff Resilience Score Comparison

For the Medical Instruments & Supplies subindustry, West Pharmaceutical Services's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

West Pharmaceutical Services Tariff Resilience Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, West Pharmaceutical Services's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where West Pharmaceutical Services's Tariff Resilience Score falls into.


WST
95GF Score
West Pharmaceutical Services Inc WST
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
West Pharmaceutical Services (WST) has a Tariff Resilience Score of 6 as of Jun. 24, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, West Pharmaceutical Services ranks #76 out of 838 companies in the Medical Devices & Instruments industry, placing it in the top 9.1%.
Is West Pharmaceutical Services' Tariff Resilience Score too high?
West Pharmaceutical Services' current Tariff Resilience Score is 6. Based on the distribution chart, West Pharmaceutical Services ranks #76 out of 838 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, West Pharmaceutical Services has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does West Pharmaceutical Services' Tariff Resilience Score compare to RMD and MDLN?
According to the Medical Devices & Instruments industry distribution chart, West Pharmaceutical Services ranks #76 out of 838 companies for Tariff Resilience Score. This places West Pharmaceutical Services in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Devices & Instruments company?
A good Tariff Resilience Score depends on the Medical Devices & Instruments industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. West Pharmaceutical Services's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is West Pharmaceutical Services stock overvalued right now?
Based on GuruFocus' analysis, West Pharmaceutical Services (WST) is currently considered Fairly Valued. The stock's GF Value™ is $361.52, compared to a current price of $341.96 — trading 5.4% below its estimated fair value. The current Tariff Resilience Score is 6. West Pharmaceutical Services' overall GF Score™ is 95/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For West Pharmaceutical Services (WST), the current Tariff Resilience Score is 6 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is West Pharmaceutical Services (WST) Overvalued in 2026?

Based on GuruFocus' analysis, West Pharmaceutical Services stock appears to be undervalued. The current stock price of $341.96 is trading 5.4% below its estimated GF Value™ of $361.52. GuruFocus considers West Pharmaceutical Services to be Fairly Valued.

Key valuation signals for WST:

  • Tariff Resilience Score: 6
  • GF Value™: $361.52 vs. price of $341.96 (5.4% below fair value)
  • GF Score™: 95/100 with 9 warning signs

No single metric tells the full story. See the WST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

West Pharmaceutical Services Business Description

Address 530 Herman O. West Drive, Exton, PA, USA, 19341-1147
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
95GF Score

Get the complete analysis for WST

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$341.96
Price
$361.52
GF Value